TY  - CHAP
M1  - Book, Section
TI  - Pharmacogenomics
A1  - Roden, Dan M.
A2  - Jameson, J. Larry
A2  - Fauci, Anthony S.
A2  - Kasper, Dennis L.
A2  - Hauser, Stephen L.
A2  - Longo, Dan L.
A2  - Loscalzo, Joseph
Y1  - 2018
N1  - 
T2  - Harrison's Principles of Internal Medicine, 20e
AB  - The  previous  chapter  discussed  mechanisms  underlying  variability  in  drug  action,  highlighting  pharmacokinetic  and  pharmacodynamic  pathways  to  beneficial  and  adverse  drug  events.  Work  in  the  past  several  decades  has  defined  how  genetic  variation  can  play  a  prominent  role  in  modulating  these  pathways.  Initial  studies  described  unusual  drug  responses  due  to  single  genetic  variants  in  individual  subjects,  defining  the  field  of  pharmacogenetics.  A  more  recent  view  extends  this  idea  to  multiple  genetic  variants  across  populations,  and  the  term  “pharmacogenomics”  is  often  used.  Understanding  the  role  of  genetic  variation  in  drug  response  could  improve  the  use  of  current  drugs,  avoid  drug  use  in  those  at  increased  risk  for  adverse  drug  reactions  (ADRs),  guide  development  of  new  drugs,  and  even  be  used  as  a  lens  through  which  to  understand  mechanisms  of  diseases  themselves.  This  chapter  will  outline  the  principles  of  pharmacogenomics,  the  evidence  as  currently  available  that  genetic  factors  play  a  role  in  variable  drug  actions,  and  outline  areas  of  controversy  and  future  work.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1155945122
ER  -